Form 4: RAPT Therapeutics Director William Rieflin Acquires Stock Options
SEC Form 4 Filing
Director William Rieflin acquired stock options in RAPT Therapeutics, Inc.
Summary
- William Rieflin, a director of RAPT Therapeutics, Inc., acquired stock options on May 23, 2024.
- The options grant the right to buy 36,490 shares of common stock at an exercise price of $4.63.
- The options vest in 12 equal monthly installments from the grant date of May 22, 2024, and expire on May 21, 2034.
- The transaction was reported on a Form 4 filing with the SEC.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard transaction. The acquisition of options by a director can be seen as a slightly positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of grant for the stock options. |
| 05/23/2024 | Date of transaction (acquisition of stock options). |
| 05/21/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.